10:31 AM EDT, 04/19/2024 (MT Newswires) -- TScan Therapeutics ( TCRX ) said Friday it closed a public offering of its securities, raising about $150.1 million in gross proceeds.

The offering comprised 2,472,581 voting common shares priced at $7.13 each and pre-funded warrants to purchase up to 18,577,419 shares at $7.1299 per warrant.

Underwriters have a 30-day overallotment option to acquire up to 3,157,500 additional shares.

The company said it plans to use the net proceeds for general corporate purposes.

TScan said it now expects its cash, cash equivalents and marketable securities to fund its current operating plan into Q4 of 2026.

The company's shares were up nearly 1% in recent trading.